SI-BONE, Inc.

SI-BONE, Inc. develops innovative procedural solutions for compromised bone, focusing on biomechanical design and anatomy-specific innovation. The company specializes in minimally invasive treatment for sacroiliac joint dysfunction and degeneration, addressing challenges in low-density bone in the sacrum. Leveraging its additive manufacturing (3D-printing) experience from sacroiliac fusion, SI-BONE has expanded its technology platform to meet needs in thoracolumbar fixation and fusion, and pelvic trauma. SI-BONE markets its products primarily through a direct sales force and third-party sales agents in the United States. In other countries, sales are conducted via a combination of a direct sales force, sales agents, and resellers. As of December 31, 2025, over 140,000 procedures have been performed using SI-BONE products since the introduction of iFuse in 2009. The company's products include patented titanium implants, the instruments for implantation, and implantable bone products. Key implant product lines include iFuse, launched in 2009; iFuse 3D, launched in 2017; iFuse TORQ, launched in 2021; iFuse Bedrock Granite, launched in 2022; and iFuse INTRA and iFuse TORQ TNT, both launched in 2024. In the United States, iFuse, iFuse 3D, iFuse TORQ, and iFuse Bedrock Granite are cleared for sacroiliac joint dysfunction, adult spinal deformity, and pelvic trauma applications. iFuse TORQ TNT is cleared for pelvic trauma and sacroiliac joint dysfunction. In the European Economic Areas, iFuse, iFuse 3D, and iFuse TORQ are CE marked for sacroiliac joint dysfunction, adult spinal deformity, and pelvic fracture fixation. The iFuse implant is a machined triangular titanium implant with a triangular cross section and porous surface, authorized by the FDA in November 2008 and CE-Marked in November 2010. iFuse 3D is a second-generation, additively-manufactured triangular titanium implant with a porous surface and fenestrated design.